Clinical Trials Browser

Recruiting × tislelizumab × Gynecologic × Clear all

NCT06063018 2023-10-02

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

Phase 2 Recruiting

Cervical Cancer Recurrent